Category Archives: Guest Blog

Drug Discovery CRO Sector to Thrive in Europe

The European pharmaceutical industry is changing its approach to R&D and is increasingly relying on outsourcing for drug discovery, writes Faiz Kermani. The European pharmaceutical industry accounts for nearly 40% of the global industry’s R&D investment. Although  companies are responding to current pressures by closing R&D sites, they still need to support their ongoing drug-development projects […]
Also posted in Europe, Events, Global, R&D | Tagged , , , | Leave a comment

Marketing is Pre-Sales

Not long ago, I was privy to a discussion taking place in a large drug development services company. Under pressure from above to increase revenues, the sales director was arguing to put more boots on the ground and hire more sales representatives; more sales reps, he contended, means more sales. The marketing director countered that […]
Also posted in Marketing, Sales | Tagged , | Leave a comment

Europe: Expectations High for Rare Disease Day

Next week Europe will celebrate Rare Disease Day. This is an interesting example – one might almost say a rare example – of a successful attempt by a European interest group to capture public attention. It is now an annual awareness-raising event co-ordinated by the European rare diseases lobby group, EURORDIS. For this year’s celebration, […]
Also posted in Europe, Events, Global, Orphan Drugs | Tagged , , , , | Leave a comment

Risk-Based Monitoring: From the Road Less Traveled to Productivity Superhighway

Risk-Based Monitoring:  From the Road Less Traveled to Productivity Superhighway By:  Mukhtar Ahmed, global vice president, life sciences strategy, Oracle Health Sciences The latest news on the growing cost of conducting clinical trials is becoming a major concern for company sponsors and trial co-operative groups.  Clinical trials cost 60% more today than they did just […]
Also posted in R&D, Regulatory, Technology | Tagged , , , , , , , | Leave a comment

Pricing Management: It's All About the Data

By James Robinson. Any pricing or revenue management initiative is only as good as the information on which it is based. However, too many pharma companies continue to adopt a fragmented, siloed data approach which fails to make the most of this critical business asset.
Also posted in Europe, pricing | Tagged , , , | Leave a comment
  • Categories

  • Meta